Skip to main content
x

Recent articles

Orca heads to the FDA

Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.

Innate shows Bicycle the path for Nectin-4

While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.

Kura’s Komet fizzles

The company heralds a pivotal win with its menin inhibitor, but investors want to see data.

Jabez heads for the clinic

JBZ-001, acquired last year, features with CD-001 and ADCE-D01 among recent clinical trial entrants.

AstraZeneca doubles down on GPC3

The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.

Pfizer drops its B7-H4 conjugate

Felmetatug vedotin’s exit could be bad news for Mersana.